Loading...
XNAS
ARTV
Market cap50mUSD
Jun 10, Last price  
2.08USD
1D
-1.42%
1Q
-66.72%
IPO
-82.33%
Name

Artiva Biotherapeutics Inc

Chart & Performance

D1W1MN
XNAS:ARTV chart
No data to show
P/E
—
P/S
201.89
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
251k
-99.25%
02,002,0004,931,00033,492,000251,000
Net income
-58m
L+111.20%
-17,991,000-71,825,000-58,388,000-27,696,000-58,493,000
CFO
-55m
L+16.03%
-13,541,000-15,304,000-50,829,000-47,430,000-55,032,000

Profile

URL
https://www.artivabio.com/
IPO date
Jul 19, 2024
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
251
-99.25%
33,492
579.21%
4,931
146.30%
Cost of revenue
67,533
64,163
64,760
Unusual Expense (Income)
NOPBT
(67,282)
(30,671)
(59,829)
NOPBT Margin
Operating Taxes
72
53
Tax Rate
NOPAT
(67,282)
(30,743)
(59,882)
Net income
(58,493)
111.20%
(27,696)
-52.57%
(58,388)
-18.71%
Dividends
Dividend yield
Proceeds from repurchase of equity
162,324
(12)
(5)
BB yield
-143.03%
Debt
Debt current
3,740
3,596
3,486
Long-term debt
24,968
30,228
35,410
Deferred revenue
15,635
Other long-term liabilities
73
241,586
115
Net debt
(156,720)
(43,147)
(63,635)
Cash flow
Cash from operating activities
(55,032)
(47,430)
(50,829)
CAPEX
(642)
(3,258)
(6,299)
Cash from investing activities
(120,463)
(25,975)
(6,299)
Cash from financing activities
162,226
24,391
(1,264)
FCF
(63,064)
(27,774)
(83,416)
Balance
Cash
185,428
76,971
102,531
Long term investments
Excess cash
185,415
75,296
102,284
Stockholders' equity
(246,810)
(181,003)
(152,591)
Invested Capital
447,878
277,486
47,093
ROIC
ROCE
EV
Common stock shares outstanding
11,259
9,355
17,583
Price
10.08
 
Market cap
113,489
 
EV
(43,231)
EBITDA
(64,851)
(28,405)
(58,671)
EV/EBITDA
0.67
Interest
Interest/NOPBT